Roche to share new Alzheimer’s disease findings from its integrated pharmaceutical and diagnostics portfolio at AAIC

Roche has confirmed it will share new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference 2026 in London, taking place from 12 to 15 July. The presentations reflect Roche’s commitment to advancing next-generation medicines and diagnostic tools with the ambition of slowing, halting, or ultimately preventing the course of Alzheimer’s disease. Across the conference, 18 oral and poster presentations are scheduled in total. Among the highlights are five oral presentations forming part of a trontinemab Featured Research Session, an oral Perspectives Session examining neuroimmune targets such as NLRP3 in the context of neurodegenerative disease, and a series of presentations exploring how Roche’s Elecsys pTau217 and pTau181 blood tests can support Alzheimer’s diagnosis in clinical practice.

“We aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer’s patients through earlier detection and intervention,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our presentations at AAIC will feature data from our expanding Alzheimer’s disease portfolio, including investigational trontinemab, neuroinflammatory approaches and blood-based diagnostics.”

“With the approval of Elecsys pTau217, our third Alzheimer’s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,” said Matt Sause, CEO of Roche Diagnostics. “For too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer’s disease.”

---

---

Related Topics and Keywords

Alzheimer’s, Roche